NEURAXPHARM Australia has announced the PBS listing of Briumvi (ublituximab) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
Briumvi is an anti-CD20 monoclonal antibody that selectively targets CD-20-expressing B-cells, which play a role in the underlying disease process in multiple sclerosis.
The 01 Jan listing occurred just seven months after it was registered on the Australian Register of Therapeutic Goods.
The reimbursement of the new MS therapy was welcomed by Clinical Professor Todd Hardy, senior staff specialist neurologist at Concord Hospital and co-director of the MS Clinic at the Brain and Mind Centre.
"MS is a heterogeneous condition, and treatment needs can differ over time," explained Professor Hardy.
"Having a variety of therapeutic options, including therapies with different administration and dosing schedules, is important as it helps clinicians tailor management to the individual needs of patients.
"The streamlined one-hour, twice-yearly dosing of Briumvi should reduce burden on both patients and infusion services."
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Jan 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Jan 26
